OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.67M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 18.67M.
Fairly Valued
The company’s latest PE is -5.29, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.62M shares, decreasing 29.21% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 9.84K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.01.